Oncologic clinical trials depend on cancer imaging expertise and reliable, accurate, consistent and reproducible tumor imaging assessment methods to evaluate treatment response.

Our team of imaging experts from Dana-Farber Cancer Institute, Massachusetts General Hospital, and Brigham and Women's Hospital has supported over 2,500 trials across a wide range of cancers, bringing a breadth of experience in tumor response assessments across all imaging modalities.

Imaging Review

Our TIMC multimodality imaging team assesses over 12,000 time points per year for over 1,800 active DF/HCC clinical trials. We support more than 30 tumor response assessment criteria, including but not limited to, RECIST 1.1, iRECIST, Lugano, LYRIC, IWCLL, RANO, PCWG3, as well as a variety of PET semi-quantitative and functional metrics, and have incorporated and implemented a wide spectrum of trial-specific modifications.

Protocol guidance

Our team makes sure that each trial's protocol is interpreted and executed as intended to support the study objectives. We help identify protocol language which may require further clarification and help determine the impact of potential gaps. Our in-depth knowledge of standardized tumor response criteria and common trial-specific modifications to these criteria ensures quality, reproducibility, accuracy and consistency across our cancer imaging reviewers.


We provide training for tumor imaging response criteria used in clinical trials. All imaging analysts and reviewers must successfully complete an online tutorial and pass a test to demonstrate their knowledge of each criteria. Imaging analysts must also undergo comprehensive reliability assessment measures, such as intra- and inter-rater reliability. Random sampling of assessments across imaging analysts, reviewers and response criteria are also conducted to ensure accuracy, consistency, reproducibility and compliance with trial-specific requirements, and a high level of agreement across imaging analysts and reviewers.